In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids

被引:147
作者
Breinholt, VM
Offord, EA
Brouwer, C
Nielsen, SE
Brosen, K
Friedberg, T
机构
[1] Danish Vet & Food Adm, Inst Food Safety & Toxicol, Div Biochem & Mol Toxicol, DK-2860 Soborg, Denmark
[2] Nestle Res Ctr, Mol Nutr Grp, CH-1000 Lausanne 26, Switzerland
[3] St Radboud, Lab Pediat & Neurol, Ctr Pediat Hematol Oncol, Nijmegen, Netherlands
[4] Univ So Denmark, Odense Univ, Inst Publ Hlth, Odense, Denmark
[5] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 4HN, Scotland
关键词
cytochrome P450; flavonoids; HPLC; CYP1A2; fluvoxamine; alpha-naphthoflavone;
D O I
10.1016/S0278-6915(01)00125-9
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Human and mouse liver microsomes And membranes isolated from Escherichia coli, which expressed cytochrome P450 (CYP) 1A2, 3A4 2C9 or 2D6, were used to investigate CYP-mediated metabolism of five selected dietary flavonoids. In human and mouse liver microsomes kaempferol, apigenin and naringenin were hydroxylated at the 3'-position to yield their corresponding analogs quercetin, luteolin and eriodietyol, whereas hesperetin and tamarixetin were demethylated at the 4'-position to yield eriodictyol and quercetin. respectively, Microsomal flavonoid metabolism as potently inhibited by the CYP1A2 inhibitors. fluvoxamine and alpha-naphthoflavone. Recombinant CYP1A2 as capable of metabolizing all five investigated flavonoids. CYP3A4 recombinant protein did not catalyze hesperetin demethylation. but showed similar metabolic profiles for the remaining compounds, as did human microsomes and recombinant CYP1A2. although the reaction rates in general were lower as compared to CYP1A2. CYP2C9 catalyzed the 4'-demethylation of tamarixetin, whereas CYP2D6 did not seem to play any role in the metabolism of the selected flavonoids. The major involvement in flavonoid metabolism of human CYP1A2, which mediates the formation of metabolites with different biochemical properties as compared to the parent compound and furthermore is known to he expressed very differently among individuals, raises the important question of whether individual differences in the CYP enzyme activity might affect the beneficial outcome of dietary flavonoids, rendering some individuals more or less refractors to the health-promoting potential of dietary flavonoids. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:609 / 616
页数:8
相关论文
共 26 条
  • [1] Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3
  • [2] Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli
    Blake, JAR
    Pritchard, M
    Ding, SH
    Smith, GCM
    Burchell, B
    Wolf, CR
    Friedberg, T
    [J]. FEBS LETTERS, 1996, 397 (2-3) : 210 - 214
  • [3] Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay
    Breinholt, V
    Larsen, JC
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (06) : 622 - 629
  • [4] Breinholt V, 1998, IN VITRO MOL TOXICOL, V11, P193
  • [5] Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability
    Breinholt, V
    Hossaini, A
    Svendsen, GW
    Brouwer, C
    Nielsen, SE
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2000, 38 (07) : 555 - 564
  • [6] Differential effects of dietary flavonoids on drug metabolizing and antioxidant enzymes in female rat
    Breinholt, V
    Lauridsen, ST
    Dragsted, LO
    [J]. XENOBIOTICA, 1999, 29 (12) : 1227 - 1240
  • [7] CYTOCHROME-P450 SPECIFICITIES OF ALKOXYRESORUFIN O-DEALKYLATION IN HUMAN AND RAT-LIVER
    BURKE, MD
    THOMPSON, S
    WEAVER, RJ
    WOLF, CR
    MAYER, RT
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 48 (05) : 923 - 936
  • [8] Bioflavonoids: selective substrates and inhibitors for cytochrome P450CYP1A and CYP1B1
    Doostdar, H
    Burke, MD
    Mayer, RT
    [J]. TOXICOLOGY, 2000, 144 (1-3) : 31 - 38
  • [9] The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study
    Edenharder, R
    Rauscher, R
    Platt, KL
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 379 (01) : 21 - 32
  • [10] Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: An intralaboratory comparison
    Friedberg, T
    Pritchard, MP
    Bandera, M
    Hanlon, SP
    Yao, D
    McLaughlin, LA
    Ding, S
    Burchell, B
    Wolf, CR
    [J]. DRUG METABOLISM REVIEWS, 1999, 31 (02) : 523 - 544